India's significant demand for gold is fueling commercial fraud and grey-market transactions. Vivek Johri, former chairman of the Central Board of Indirect Taxes and Customs, notes an increase in seizures and smuggling methods. Vipul Shah, chairman of the Gem and Jewellery Export Promotion Council, calls for a reduction in gold import duty to 4 percent. Somasundaram P.R., regional CEO of the World Gold Council, advocates for the establishment of a self-regulatory organization.

The Serum Institute of India has requested the union health ministry to include its COVID vaccine Covovax on the CoWIN portal as a heterologous booster dose for adults. The request was made by Prakash Kumar Singh, Director of Government and Regulatory Affairs at SII. The National Technical Advisery Group on Immunisation is expected to meet soon to make a decision. Covovax has received market authorization from the Drugs Controller General of India as a booster for those who have received Covishield or Covaxin. The vaccine, developed through technology transfer from Novavax, has also been approved by the EMA and received WHO's Emergency Use Listing.

China has approved the sale of Pfizer's COVID-19 pill, Paxlovid, following the country's shift from its 'zero-COVID' policy. China Meheco Group has signed an agreement with Pfizer to import and distribute the drug, which is now available for retail sale. The first retail sale saw the drug sell out within half an hour. Dr Ashish Jha from the White House stated that the Biden administration was not involved in the approval process but supports global access to American scientific innovations.

The European Union plans to revise its pharmaceutical legislation to address medicine shortages, particularly antibiotics, which have been reported in 26 European countries. Health Commissioner Stella Kyriakides emphasized the need for stronger supply obligations and earlier shortage notifications. The European Commission's proposal is expected in March. The shortages are attributed to an early rise in respiratory infections and limited production capacity. The EU is exploring regulatory options and engaging with companies to boost production. The Health Emergency Preparedness and Response Authority may also procure medicines to mitigate shortages.

The European Union has launched the European Cancer Imaging Initiative to aggregate cancer imaging data, aiming to accelerate innovation and early diagnosis using AI. The project aligns with the EU's data strategy and GDPR compliance. Health Commissioner Stella Kyriakides emphasized the role of digital technology in understanding cancer. Companies like Philips, Siemens Healthineers, and Bayer are involved, with Bayer recently acquiring Blackford Analysis to enhance AI diagnostic capabilities. Stakeholders express strong support for the initiative, highlighting its potential to advance medical research and diagnostic tools.

California is suing major insulin manufacturers Eli Lilly, Novo Nordisk, and Sanofi, along with the largest Pharmacy Benefit Managers (PBMs) UnitedHealth Group, CVS Health, and Cigna, for allegedly overcharging patients for insulin. The lawsuit claims these companies used their market dominance to inflate prices, violating California's Unfair Competition Law. The state seeks to halt these practices and obtain damages for affected patients. Insulin prices have significantly increased, with reports showing substantial price hikes by these manufacturers since the drugs' initial launches.

Eli Lilly is set to invest an additional $450 million to expand its North Carolina plant, aiming to boost production capacity ahead of an anticipated approval for its obesity drug, Mounjaro. The company has faced strong demand for its incretin products, including Trulicity, which has led to shortages. The expansion will add parenteral filling, device assembly, and packaging capacity, creating at least 100 new jobs by 2027. Analyst Chris Shibutani projects Mounjaro to generate significant sales, driving future growth for Eli Lilly. Since 2020, the company has committed $1.7 billion to the development of the Research Triangle Park site.

AbbVie and Eli Lilly have exited the UK's voluntary medicines pricing agreement due to unsustainable repayment rates, which surged to 26.5% of revenue in 2023. The Association of the British Pharma Industry (ABPI) argues that the current scheme has harmed innovation and seeks early talks with the government for a new settlement. The NHS's demand and use of new medicines have outpaced pre-pandemic projections, driving repayment rates to unsustainable levels. The current scheme, rooted in the NHS's foundation, will end in December.

The USFDA has granted an appeal for Ardelyx’s experimental kidney disease drug, tenapanor, after previously delaying its decision. This news led to a significant rise in Ardelyx’s shares. The FDA's advisory committee had earlier voted for the drug's approval both as a single therapy and in combination with existing treatments for controlling high phosphate levels in dialysis patients. Tenapanor, also known as Ibsrela, is already approved for treating irritable bowel syndrome in the US and Canada. Ardelyx had reacquired the drug rights from AstraZeneca in 2015.

Scientists from Mumbai’s Tata Institute of Fundamental Research, the Agharkar Research Institute in Pune, and IIT Hyderabad have discovered a new drug molecule, Ruthenium-Ferrocene Bimetallic, showing high anti-tumor potential and anti-angiogenic effects. This development is significant due to the limitations of current platinum drugs, which often face resistance. The research, led by Malay Patra, has shown promising results in cellular models and zebrafish, with plans to test on mammals. The findings have been published in the ACS journal, indicating potential for managing platinum-resistant cancers.

The European Medicines Agency (EMA) is considering issuing guidance for physicians using Novartis's gene therapy Zolgensma, advising them to monitor patients for liver injury following recent deaths due to liver failure. Novartis reported two fatalities in August from acute liver failure after Zolgensma treatment, which is used for spinal muscular atrophy. The guidance, pending approval from EMA expert panels, suggests consulting specialists and adjusting corticosteroid regimens if patients do not respond adequately. Zolgensma, which costs over $2 million per patient, competes with Roche's Evrysdi and Biogen's Spinraza.

The USFDA has issued a Complete Response Letter (CRL) for Biocon Biologics' application for Insulin-R, a proposed biosimilar for diabetes treatment. The CRL indicates that the application cannot be approved in its current form and requires additional data and satisfactory implementation of a Corrective and Preventive Action Plan (CAPA) related to a pre-approval inspection of Biocon's Bengaluru facilities. Biocon Biologics is working to address the CRL comprehensively.

A partnership was signed to ensure large-scale production of the Lumpi-ProVac vaccine to control Lumpy Skin Disease (LSD) in India. The vaccine, developed by ICAR-NRCE and ICAR-IVRI, is effective and safe, providing protection for about a year. Agrinnovate India granted non-exclusive rights for its commercial production to the Institute of Veterinary Biological Products. The initiative is supported by the Ministry of Agriculture and Farmers’ Welfare, with significant involvement from various research centers. LSD has caused significant cattle mortality since 2019, prompting the development of this indigenous vaccine.

The US government's plan to curb drug prices through the Inflation Reduction Act could negatively impact Novartis's research in small-molecule drugs, which are crucial for innovative treatments. Novartis urges reconsideration of the legislation, highlighting the potential unintended consequences on patient care and pharmaceutical innovation. The company aims to prioritize growth in the US market while maintaining its leading position in Europe.

The Drug Controller General of India has approved the COVID-19 vaccine Covovax, developed by the Serum Institute of India, for use as a heterologous booster dose for adults who have received two doses of Covishield or Covaxin. This decision follows recommendations from the Central Drugs Standard Control Organisation's Subject Expert Committee. Covovax, manufactured through a technology transfer from Novavax, has previously received conditional marketing authorisation from the European Medicines Agency and Emergency Use Listing from the World Health Organization. The approval aims to address the escalating COVID-19 situation in some countries.

Adar Poonawalla emphasizes the need for vaccine equity and global harmonization of regulatory standards to enhance real-time impact. He advocates for international agreements on vaccine certificates and clinical trial procedures to avoid delays. Highlighting the importance of multi-lateral cooperation, Poonawalla is optimistic about future pandemic preparedness. He underscores India's significant role in global vaccine manufacturing and mentions upcoming vaccines for cervical cancer and malaria. Michelle Williams from Harvard TH Chan School of Public Health stresses the ongoing threat of COVID-19 variants and the necessity for continued vigilance.

Pfizer is considering various options for its early-stage treatments for rare diseases and cancer to concentrate on high-impact medicines and vaccines. The company may collaborate with other drug developers or establish a new company for these treatments. Pfizer aims to focus on developing rare disease treatments internally using technologies like gene editing while exploring external opportunities for early-stage gene therapy programs and its cancer research facility in Boulder, Colorado.

The National Pharma Pricing Authority (NPPA) has revised the ceiling prices of 128 drugs, including antibiotics, anti-viral medications, and treatments for conditions such as asthma, cancer, and brain tumors. The new prices include Rs 2.18 for an Amoxicillin capsule and Rs 1.07 for a 400 mg Ibuprofen tablet. Manufacturers must adjust their prices to comply with these new ceilings. Additionally, the NPPA has set retail prices for 12 scheduled formulations under the Drugs (Prices Control) Order, 2013, including Rs 13.83 for an anti-diabetes combination drug tablet.

Malaria No More's India director, Pratik Kumar, discusses the challenges and necessary actions for malaria eradication in India. He highlights the discrepancies in malaria data reporting between the government and WHO, the inefficiencies in the current health system, and the need for a collective societal effort to eliminate malaria by 2030. The text criticizes the government's lack of urgency and effective action, emphasizing the importance of involving all sectors and making malaria eradication a people's movement.

India aims to eliminate malaria by 2030, facing challenges such as high mosquito larva presence near water bodies and lack of awareness. Despite an 80% reduction in cases since 2014, concentrated efforts are needed in tribal-populated states. Experts highlight the importance of vector control, accurate case reporting, and skilled technicians. The Vector Control Research Centre and National Institute of Malaria Research are conducting studies and trials to improve vector surveillance and control methods. Public health experts emphasize the need for environmental methods to prevent mosquito breeding, while the WHO's 1-3-7 model serves as a successful example.

The National Pharmaceutical Pricing Authority (NPPA) of India announced a 12.12% increase in medicine prices based on the Wholesale Price Index (WPI) rate for pharmaceuticals for 2022, effective from April 1. However, a subsequent clarification revealed an average price reduction of 6.73% for 651 of 870 essential medicines. Despite the confusion, the pharmaceutical industry has faced significant cost increases in raw materials, packaging, and transportation, necessitating the price hike. The NPPA is also actively monitoring for illegal price hikes. While the government has been praised for capping prices of essential medicines, the regulation of non-essential drug prices remains a challenge.

Pharma major GSK has introduced Shingrix, a shingles vaccine, which is now available in over 20 countries, including India. Shingles, a disease caused by the reactivation of the chickenpox virus, predominantly affects the elderly. Experts highlight the high efficacy of Shingrix in preventing shingles and its complications, particularly postherpetic neuralgia. The vaccine's affordability in India is crucial for reducing the disease's incidence and severity. However, challenges such as lack of awareness and market access could impact its uptake. Two doses of Shingrix are recommended for adults aged 50 and above.

India has the second largest population of hemophilia patients, with over 1.3 lakh cases. The blood disorder, which impairs clotting, is often undiagnosed due to poor screening facilities. Roche Pharma India's CEO V Simpson Emmanuel highlights the challenges in diagnosis and treatment, while Dr Chandrakala S from KEM Hospital in Mumbai notes the need for regular replacement therapy, which is not widely available. Roche launched Hemlibra in 2019, a bi-specific antibody treatment for hemophilia. The government has removed customs duty on rare diseases drugs, with calls to include all anti-hemophilic drugs.

Health experts warn of an increase in heatstroke-related deaths due to rising temperatures and climate change. Maharashtra has already recorded 14 deaths, and experts like Dr Rajendra Gupta emphasize the need for government action and public awareness. Common causes and symptoms of heatstroke are highlighted, along with preventive measures. The article stresses the importance of hydration and avoiding outdoor activities during extreme heat, particularly for vulnerable populations such as the elderly.

Rajni Sekhri Sibal's book 'The Guru – Guru Nanak’s Saakhis' explores the life and teachings of Guru Nanak, emphasizing his wisdom, compassion, and belief in equality. The book, structured in 10 chapters, delves into Nanak's early life, his philosophical inquiries, and his spiritual journey. Sibal's narration is praised for its simplicity and effectiveness, making the reader feel connected to Nanak's experiences. The foreword by Nobel laureate Kailash Satyarthi highlights the book's thought-provoking nature and its potential to guide readers towards a purposeful life.

The C20 India summit, an official engagement group of G20, convened in Faridabad, Haryana, to discuss integrated holistic health. Global healthcare experts, including WHO Director-General Tedros Adhanom Ghebreyesus, emphasized the need for universal health coverage and reorienting health systems towards primary healthcare. The summit addressed key health challenges such as mental health, nutrition, and the integration of traditional medicine. Haryana Chief Minister Manohar Lal Khattar highlighted the importance of a balanced lifestyle and Ayurveda. Recommendations from the summit will be sent to Prime Minister Narendra Modi for final policy framing.

The article discusses the enduring charm of Urdu literature, particularly poetry, in the modern digital age. It highlights the efforts of the Rekhta Foundation, which is dedicated to preserving Urdu poetry and literature, and their recent event 'Shaam-e-Sher' that catered to young poets and Urdu enthusiasts. The event saw participation from a diverse audience, including many from non-Urdu backgrounds, indicating a growing interest in Urdu poetry among the youth. The article features quotes from participants and poets who express their admiration for the language's elegance and emotional depth. Veteran poet Shamim Hanafi's observations suggest optimism for the future of Urdu literature, especially with the increased involvement of younger generations.

Robotic surgeries in India are still in their early stages, contributing less than 0.1% globally. Awareness and training for robotic surgeries are limited, and high costs are a significant barrier. Dr. Sudhir Srivastava, MD and Chairman of SSI Innovations, developed India's first Made-in-India surgical robot, SSI Mantra, to make robotic surgeries more affordable. SSI Mantra has been deployed in several hospitals across India. The DaVinci surgical system by Intuitive Surgical is commonly used but is expensive. Challenges include high costs, limited instrument usage, and the need for stable internet connectivity for remote surgeries. SSI Innovations is seeking USFDA approval for SSI Mantra.

Virologist Dr Gagandeep Kang from Christian Medical College, Vellore, discusses the recent increase in Covid-19 cases in India, emphasizing that the rise is not alarming due to the population's existing immunity levels. She argues against the feasibility of universal masking and daily testing, suggesting that individuals should assess their own risk levels and act accordingly. Dr Kang highlights that while Covid-19 is not going away, the current situation is not as severe as previous waves, and most infections are mild.

From April 1, the prices of 384 essential medications and over 900 formulations will increase by more than 12% due to a rise in the Wholesale Price Index (WPI). This development is expected to provide relief to the pharmaceutical industry, which has been struggling with increased production costs since the COVID-19 pandemic. The National Pharmaceutical Pricing Authority (NPPA) announced the change, which has raised concerns about the affordability of essential medicines. Rajiv Singhal from the All India Organisation of Chemists and Druggists supports the increase, while Malini Aisola from the All India Drug Action Network warns that it could undermine price controls for essential medicines.

The Rajasthan assembly passed the Right To Health (RTH) Bill, mandating emergency care in private hospitals without prepayment, leading to protests from private doctors. They argue the bill's ambiguity and low reimbursement rates unfairly burden the private sector. The Indian Medical Association criticizes the lack of expert consultation, while public health activist Bejon Misra supports regulation. Dr. Manoj Mahajan highlights the challenges for small private clinics and suggests strengthening government healthcare infrastructure instead.

Experts emphasize the importance of public surveillance and Covid-appropriate behavior as cases of Covid-19 and H3N2 influenza rise. They recommend measures such as self-isolation for symptomatic individuals, mask-wearing in crowded places, social distancing, and increased testing and genomic surveillance. Healthcare professionals stress the need for proactive surveillance, adequate hospital resources, and support for healthcare workers. The article highlights the necessity of adopting Covid-appropriate behavior as a permanent lifestyle change to manage the spread of various flu strains.

Medical Excellence Japan (MEJ) has proposed the establishment of Medical Excellence India (MEI) to enhance the healthcare ecosystem through multi-sectoral collaboration. A joint workshop in Delhi discussed improving acute medicine in India with insights from Japan. Key stakeholders, including NITI Aayog, MEA, and ICMR, participated. Proposals included Advanced Air Mobility for healthcare and tech collaborations. MEJ aims to build overseas medical bases and foster international medical collaboration. The India-Japan Public-Private Conference on Healthcare showcased Japanese companies' contributions to India's healthcare infrastructure.

The article discusses the challenges faced by women in leadership and various fields, highlighted during the sixth edition of 'We The Women' event organized by Barkha Dutt in Jaipur. Key speakers included politicians, celebrities, and community leaders who shared personal experiences of online trolling, workplace harassment, and societal pressures. Notable mentions include Jacinda Ardern, Nicola Sturgeon, Kushboo Sundar, Vidya Balan, and Hillary Clinton, who emphasized the need for resilience and change in societal attitudes towards women.

Health experts urge vigilance against the Influenza A-H3N2 virus, which shares symptoms with COVID-19 but is less infectious. Dr. Sushila Kataria from Medanta and Dr. Manoj Goel from Fortis Memorial Research Institute note an increase in flu cases, particularly among vulnerable groups. Dr. Manoj Kumar from Narendra Mohan Hospital highlights under-reporting in several Indian states and calls for increased screening. The World Health Organization emphasizes the virus's impact on developing countries. Preventative measures include vaccination, masking, and avoiding crowded spaces.

The article discusses the silence and stigma surrounding menstruation and menopause in India, highlighting personal stories and expert opinions. It emphasizes the need for open conversations and awareness to de-stigmatize these natural biological processes. Key figures like Asha Rao and Monalisa Padhee are noted for their advocacy work, while experts like Dr. Nozer Sheriar and Dr. Sunila Khandelwal provide insights into the symptoms and societal perceptions of menopause. The article also references UNICEF data on menstruation awareness among adolescent girls in India.

We The Women (WTW) festival, a platform celebrating women's achievements and discussions on their challenges, is being organized in Jaipur on March 4. The event will feature a range of speakers including actor-turned-politician Khushboo Sundar, actresses Vidya Balan and Jhanvi Kapoor, businesswoman Ghazal Alagh, and Neelam Krishnamurthy, an advocate for Uphaar tragedy victims. Aditya Roy Kapur will speak on masculinity, and a video conversation with Hilary Rodham Clinton is also scheduled. The forum, founded by journalist Barkha Dutt, has previously been held in four other Indian cities with over 500 speakers.

Archaeological research and education in India are not meeting the needs of students like Anushree, who pursued higher education abroad at Durham University due to a lack of opportunities in Indian institutions. Experts like Professor K. Krishnan from Baroda University acknowledge the potential for archaeological studies in India but note the absence of the necessary push and opportunities. Durham University's Department of Social Sciences and Health has partnered with Indian institutions to enhance archaeological research through joint research, workshops, faculty exchange, and training. This collaboration aims to improve learning for archaeology students and support India's research system.

The 22nd World Sustainable Development Summit 2023, organized by The Energy and Resources Institute (TERI) in New Delhi, emphasized the urgent need for increased climate finance. Experts, including Amitabh Kant from the Ministry of External Affairs, highlighted India's potential to meet decarbonization targets and the necessity of reducing green hydrogen costs. Jagjeet Singh Sareen from Dalberg Advisors and Mahendra Singhi, CEO of Dalmia Cement, stressed the importance of expanding climate finance and developing specific strategies to address climate change. Dr. Dhruba Purkayastha from the Climate Policy Initiative pointed out the significant global gap in climate investments, advocating for an institutional mechanism to ensure effective use of funds.

Encephalitis, a severe inflammation of the brain, affects one person every minute globally, yet remains largely unknown to the public. Dr. Ava Easton from The Encephalitis Society discusses the causes, symptoms, and treatments of the disease, emphasizing the need for increased awareness. The condition can result from infections or autoimmune responses, leading to high mortality rates and long-term cognitive and physical impairments. Recent advancements in diagnostic and treatment technologies show promise, but accessibility remains an issue, especially in low-income regions. Preventive measures include vaccinations and public education. The Encephalitis Society actively raises awareness and supports affected individuals, with initiatives like World Encephalitis Day. Collaborative efforts with global stakeholders, including WHO, aim to improve the understanding and management of encephalitis.

The Ministry of Health and Family Welfare has appointed Dr. P.B.N. Prasad as the new Drugs Controller General of India (DCGI) on a temporary basis, succeeding Dr. V.G. Somani. Dr. Prasad will hold the position until February 28 or until further orders. The Union Public Service Commission (UPSC) has recommended three candidates for the permanent position, including Dr. Rajeev Raghuvanshi, Dr. Somani, and Dr. Prasad, with the final decision pending.

Global healthcare experts emphasize the urgent need for digital solutions to improve healthcare infrastructure, especially highlighted by the challenges faced during the Covid-19 pandemic. In India, the Ministry of Health and Family Welfare approved telemedicine to treat virus patients, accelerating the adoption of technology in healthcare. Experts like Professor Ilona Kickbusch and Dr. Ratna Devi stress the importance of digital health systems and patient empowerment. The Ayushman Bharat Digital Mission (ABDM) is making significant strides with over 32 crore health accounts created. Comparisons with the Netherlands' healthcare system highlight the potential for international partnerships to create cost-effective solutions.

The India Art Fair 2023 in New Delhi showcases a blend of art and technology, featuring 85 exhibitors, including 71 galleries and 14 institutions. The event, in partnership with BMW India, highlights digital and contemporary artworks, with a special focus on the 'Digital Artist in Residence' program. Notable works include Devika Sundar's design on the BMW X7, Mira Felicia Malhotra's AR portraits exploring gender roles, Gaurav Ogale's audio-visual book series, and Varun Desai's AI-infused projection room. The fair emphasizes the theme of 'Forwardism,' merging art, science, and fiction.

Bharat Biotech chairman Dr Krishna Ella advocates for merging state and central Food and Drug Administrations in India to ensure uniform quality standards amid criticism over drug manufacturing lapses. He emphasizes the need for a centralized regulatory system and highlights the political nature of the decision. The call comes as India faces scrutiny over drug-related deaths abroad. Dr Ella also discusses Bharat Biotech's preparedness for future health crises and ongoing vaccine development. The article also covers the partnership between the Ella Foundation and the University of Wisconsin-Madison Global Health Institute to establish a health center in Bengaluru, aimed at advancing vaccine research and development.

The Indian Pharmacopoeia Commission (IPC) is planning to digitise the Indian Pharmacopoeia (IP) to increase reach, offer flexible pricing, and conduct better research on its usage. The digitisation will also help prevent counterfeiting and improve services by tracking product usage. IPC is also working on digitising its internal processes through an Enterprise Resource Planning (ERP) system and converting its library into a digital product. The digitisation process is currently in the tender phase, with an expert committee evaluating vendors. The article highlights the challenges faced by MSMEs in the pharma industry regarding digitisation due to lack of skills and finances.

Union Finance Minister Nirmala Sitharaman allocated Rs 495 crore for the Global Fund Grant under the Covid-19 Response Mechanism in India's union budget for 2023-2024. The Ministry of Health and Family Welfare received a total revenue of Rs 1,04,683 crore, with some budgetary decreases in grants-in-aid to state governments and capital outlay for medical and public health. However, there were increases in allocations for the Central Government Health Scheme, Safdarjung Hospital, and other medical institutions. The Pradhan Mantri Ayushman Bharat Health Infrastructure Mission and Ayushman Bharat - Pradhan Mantri Jan Arogya Yojana saw significant budget increases, while the Pradhan Mantri Swasthya Suraksha Yojana experienced a decrease. The National AIDS and STD Control Programme and the National Organ Transplant Programme received higher allocations, with no change in the National Rural Health Mission funding.

The Union budget for 2023-2024 has significantly increased funding for the AYUSH sector, reflecting the growing demand for traditional medicine post-Covid-19. The Ministry of AYUSH's grants-in-aid to state and UT governments have seen substantial increases. However, funding for the National Pharmacovigilance Programme and laboratories for managing epidemics has decreased. The budget also emphasizes mental health, with increased allocations for the National Tele Mental Health Programme and the Post Graduate Institute of Medical Education and Research (PGIMER). The National Digital Health Mission has received a significant boost to support a comprehensive digital health ecosystem.

Granules India reported a 23% increase in third-quarter profit, driven by strong demand for paracetamol. Consolidated profit rose to Rs 1.24 billion, with revenue increasing nearly 15% to Rs 11.46 billion, primarily due to higher paracetamol API sales in the US. Chairman Krishna Prasad Chigurupati highlighted ongoing opportunities in paracetamol and expansion strategies in Europe. The company also noted significant revenue contributions from finished dosages, APIs, and pharma formulation intermediates. Shares of Granules India saw a slight increase following the results.

Sun Pharma has launched Sezaby, a phenobarbital sodium injection, in the US for treating neo-natal seizures. Sezaby is the first FDA-approved product for this condition in infants, free from benzyl alcohol and propylene glycol. The product has been granted 'orphan drug' status by the FDA, and Sun Pharma's CEO, Abhay Gandhi, emphasizes its potential impact on patients and families.

The Ministry of AYUSH has signed a Memorandum of Understanding with the India Tourism Development Corporation to promote Medical Value Travel in Ayurveda and other traditional medicinal systems. The MoU includes training for ITDC officials, identification of tourist circuits, and the inclusion of historical heritage sites in tourism offerings. A Joint Working Group will monitor the MoU's implementation and progress, drawing on best practices from countries like Malaysia, Singapore, and Thailand. The growth of the AYUSH-based healthcare and wellness economy is significant, with an estimated increase to 70 billion dollars by 2025.

Sinopharm's biotech unit in Shanghai has received approval from the National Medical Products Administration for clinical trials of its mRNA COVID-19 vaccine targeting the Omicron variant. The unit has a production capacity of two billion doses annually. Sinopharm is also the China distributor of Merck & Co's COVID-19 antiviral treatment molnupiravir, sold under the brand name Lagevrio, which was recently launched in the Chinese market.

Lupin is recalling 16,056 bottles of Rifampin capsules in the US due to a manufacturing issue identified by the United States Food and Drug Administration. The recall is prompted by failed impurities and degradation specifications observed during a long-term stability study. The affected lot was produced at Lupin's Aurangabad plant and marketed in the US by Lupin Pharma.

Israel's health ministry has found no evidence linking strokes to Pfizer and BioNTech's updated COVID-19 vaccine, despite a US safety monitoring system flagging a potential link in older adults. The USFDA and CDC's preliminary data suggested a possible connection, but Israel's reexamination of data found no such link. The EU's drug regulator also reported no safety signals related to the vaccine. Pfizer and BioNTech acknowledged limited reports of ischemic strokes in older adults but stated no evidence supports an association with their vaccine.

Johnson & Johnson has terminated a global late-stage trial of an HIV vaccine due to its ineffectiveness in preventing infections. This follows a previous failure of another J&J HIV vaccine study. The trial, which started in 2019, involved around 3,900 gay men and transgender individuals, administering two types of shots over four visits. Despite the setback, research partners like NIAID and HVTN remain committed to pursuing an effective HIV vaccine. The WHO reports that in 2021, approximately 650,000 people died from HIV-related causes, and 1.5 million new infections occurred. Other HIV vaccine candidates are in trial, including those from Moderna Inc. J&J's shares fell 1.3% following the announcement.

Sanofi anticipates a decision in its arbitration with Boehringer Ingelheim over Zantac-related cancer claims in the US by the end of the first quarter. The dispute concerns Sanofi's obligations after acquiring Zantac's marketing rights from Boehringer in 2017. Sanofi's shares rose nearly one percent following the announcement. Thousands of US lawsuits claim Zantac caused cancer, but a federal judge recently dismissed about 50,000 claims due to lack of scientific backing. Sanofi expects its fourth-quarter results to benefit from a stronger dollar and increased flu vaccine sales, with currency movements boosting sales and core earnings per share.

Moderna's experimental mRNA vaccine for Respiratory Syncytial Virus (RSV), mRNA-1345, showed 83.7% efficacy in preventing symptoms like cough and fever in a late-stage trial with adults aged 60 and older. RSV causes significant mortality among older adults, and Moderna's vaccine is compared favorably to Pfizer's and GSK's, which are also in development. The RSV vaccine market is potentially worth over $10 billion, with half expected from the US. Moderna plans to seek global regulatory approval in the first half of 2023, and the vaccine is generally safe with no myocarditis concerns.

Moderna's CEO, Stephane Bancel, expressed his ambition to establish MRNA vaccine manufacturing facilities on every continent, with current plans for factories in Canada, Australia, Britain, and Kenya. This expansion aims to enhance global vaccine production capabilities. The announcement was made during a panel at the World Economic Forum in Davos, emphasizing Moderna's commitment to global health and preparedness.

The US Food and Drug Administration has issued a warning letter to Sun Pharma for significant violations of Current Good Manufacturing Practice regulations at its Halol plant in Gujarat. The violations include failure to prevent microbiological contamination of drug products, rendering them adulterated. The facility was inspected from April 26 to May 9, 2022.

The Serum Institute of India has begun supplying Covishield vaccines to the Indian government at no cost, with the initial dispatch of 80 lakh doses occurring on January 14, 2023. This is part of a larger commitment to provide two crore doses valued at Rs 410 crore. SII has already supplied 170 crore doses of Covishield since the start of the vaccination campaign.

US Senator Bernie Sanders has urged Moderna to halt planned price increases for its COVID-19 vaccine, arguing that such hikes would make the vaccine unaffordable for many Americans, especially after significant government funding for its development. Sanders criticized the proposed price range of $110 to $130 per dose, highlighting the disparity with earlier prices and the potential financial burden on taxpayers. Moderna, while still in discussions about pricing, maintains that the new prices reflect the vaccine's value. Sanders' stance is part of his broader agenda against high drug prices and corporate greed.

AbbVie has increased its 2025 sales forecast for its immunology drugs Skyrizi and Rinvoq to over $17.5 billion, aiming to compensate for the anticipated revenue decline from its rheumatoid arthritis drug Humira. The company's previous forecast was over $15 billion, and it now expects peak sales to surpass $21 billion by 2027. AbbVie's strategy involves negotiations with insurers and pharmacy benefit managers for Humira, with its sales this year being influenced by the pricing of competitive drugs.

Merck & Co announced it would initiate legal proceedings against certain pharmaceutical companies for supplying COVID-19 drugs to various provinces and cities in China under the pretense of Merck authorization. The company clarified that Sinopharm is the sole authorized distributor of its COVID-19 antiviral drug molnupiravir, marketed as Lagevrio, which was co-developed with Ridgeback Biotherapeutics. Merck is in discussions with Sinopharm regarding a production technology license, and China National Biotec Group, a Sinopharm affiliate, is expected to manufacture the drug.

Eisai has submitted a marketing application to the European health regulator for its Alzheimer's drug lecanemab, developed in partnership with Biogen. The drug, which has received accelerated approval in the US, targets amyloid beta deposits in the brain. Eisai plans to seek marketing authorization in Japan by the end of the business year on 31st March.

Pharma companies Innova Captab and Blue Jet Healthcare have received approval from the Securities and Exchange Board of India (SEBI) to raise funds through Initial Public Offerings (IPOs). Innova Captab's IPO includes a fresh issuance of equity shares worth Rs 400 crore and an offer for sale (OFS) of 96 lakh equity shares by promoters and other shareholders. Blue Jet Healthcare's IPO is entirely an OFS of up to 21,683,178 equity shares by its promoters. The funds raised by Innova Captab will be used for debt repayment, subsidiary loan payments, and working capital requirements.

AstraZeneca plans to acquire clinical-stage biopharma firm CinCor Pharma for approximately $1.8 billion, aiming to bolster its portfolio of heart and kidney drugs. The purchase price of $26 per share represents a 121% premium over CinCor's closing stock price. Additionally, the deal includes a contingent value right of $10 per share, contingent upon a regulatory submission for CinCor's baxdrostat, a treatment for cardio-renal diseases.

Marion Biotech's production license has been suspended following allegations linking its cough syrups, Dok-1 Max and Ambronol, to the deaths of children in Uzbekistan. The World Health Organization issued a medical product alert, identifying the syrups as substandard due to toxic contaminants. India's Central Drugs Standard Control Organization is investigating, and further inspections have been conducted. The syrups were not sold in India but exported to Uzbekistan. The situation is under scrutiny by both Indian and Uzbekistani authorities.

BioNTech has agreed to acquire the British AI startup InstaDeep for up to 562 million pounds to enhance its biotech research capabilities. The deal includes an upfront payment of 362 million pounds and up to 200 million pounds contingent on InstaDeep's future performance. This acquisition aligns with BioNTech's strategy to integrate AI into its operations, particularly in developing new cancer immunotherapies and other vaccines. InstaDeep will continue to provide AI and ML services to other companies, including Google and Nvidia. The announcement was made during the JP Morgan healthcare conference.

German expatriates in China have started receiving the BioNTech COVID-19 vaccine, marking the first distribution of a foreign vaccine in China, which has previously only used domestic vaccines. This follows an agreement from Chancellor Olaf Scholz's visit to Beijing in November. Over 8,000 doses have been shipped, with more than 1,500 Germans registering interest. The arrangement, which is reciprocal, also allows Chinese nationals in Germany to receive China's SinoVac vaccine. The EU has offered free vaccines to China, but the Chinese Foreign Ministry claims their supplies are sufficient.

The USFDA has approved retail pharmacies to distribute abortion pills, specifically mifepristone, marking a significant regulatory change. This decision follows the relaxation of risk evaluation and mitigation strategies initially announced in December 2021. Danco Laboratories and GenBioPro, the manufacturers of mifepristone, have received FDA approval for their supplemental applications. Despite this change, access to the medication remains uneven due to state-level abortion bans following the US Supreme Court's overturning of Roe v. Wade. Major pharmacy chains like CVS Health and Walgreens are currently assessing the new certification requirements.

Geron's experimental blood cancer drug imetelstat demonstrated efficacy in a late-stage trial by increasing the number of patients achieving transfusion independence compared to a placebo. The trial results showed 40% of patients on imetelstat were transfusion-independent for eight weeks, versus 15% on placebo. Geron plans to seek US approval in mid-2023, EU approval in the second half of 2023, and launch commercially in 2024, with a projected peak market potential of $1.2 billion. The drug also met a secondary goal, with 28% of patients avoiding transfusions for 24 weeks. Adverse effects were consistent with previous trials. Geron is also evaluating imetelstat for myelofibrosis, with results expected in 2024, potentially competing with Incyte's Jakafi.

Macleods Pharma is recalling approximately 10,000 bottles of generic antibiotic medication in the US market due to a labeling error, as reported by the USFDA. The recall involves 10,052 bottles of Levofloxacin tablets, used for treating bacterial infections, due to mismatched embossing on the tablets and package insert. The affected lot was manufactured in Baddi, Himachal Pradesh, and the recall was initiated on January 5th in the US and Puerto Rico.

Drugmakers including Pfizer, GlaxoSmithKline, Bristol Myers Squibb, AstraZeneca, and Sanofi plan to raise prices on over 350 drugs in the US in early January. The increases are in response to the upcoming Inflation Reduction Act, inflation, and supply chain constraints. Pfizer will see the most increases, followed by GSK, Bristol Myers Squibb, AstraZeneca, and Sanofi. The median drug price increase last year was 4.9%, with the average at 6.4%, both below US inflation rates. Companies justify the hikes by citing factors like inflation, the value of therapies, and manufacturing costs.

Dr Reddy’s Laboratories reported a 77% increase in consolidated net profit, reaching Rs 1,247 crore for the third quarter ending December 31, 2022, compared to Rs 706 crore in the same period the previous year. Revenue from operations rose to Rs 6,770 crore from Rs 5,320 crore year-over-year.

In 2022, the median price of new drugs in the US exceeded $200,000, with the median annual price for 17 novel drugs approved since July being $193,900. Despite new legislation aimed at controlling drug prices, pharmaceutical companies continue to set high launch prices, particularly for treatments of rare diseases. The Inflation Reduction Act allows Medicare to negotiate prices for certain drugs but does not cap prices for new medications. The analysis highlights the ongoing trend of rising drug prices, with experts suggesting that further legislative action may be necessary.

Global public health experts, including those from India, have emphasized the urgent need to develop antibiotics for newborns, who are increasingly resistant to existing treatments. Approximately 2.3 million newborns die annually from severe bacterial infections, with 50-70% of common pathogens showing high resistance to first and second-line antibiotics. The paper, co-authored by experts from GARDP and AIIMS, calls for a global consensus to streamline antibiotic development and access for neonatal populations. Collaborative networks like the one between GARDP, Penta, SGUL, and others have been successful, as seen in a global observational study of neonatal sepsis. However, challenges such as ethical concerns and regulatory issues hinder clinical research in newborns, with only four of the 40 antibiotics approved since 2000 including dosing information for newborns.

The article discusses the challenges faced by the Pradhan Mantri Bharatiya Janaushadhi Pariyojana (PMBJP), a scheme introduced by the Indian government to provide affordable generic medicines to the public. Despite its noble intent, the scheme is plagued by operational issues such as supply chain inefficiencies, stock shortages, and payment delays to suppliers. Stakeholders, including store operators and pharmaceutical companies, express their concerns over the execution of the scheme. The article highlights specific instances where patients were unable to obtain necessary medications due to stock unavailability. It also covers the difficulties faced by pharma companies in receiving timely payments and the lack of tracking mechanisms for products. The CEO of BPPI acknowledges the need for improvement and the article calls for better planning and systems to address these issues.